JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

5.64 -3.75

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.64

Max

5.83

Põhinäitajad

By Trading Economics

Sissetulek

31M

-172M

Müük

4.4M

19M

Kasumimarginaal

-899.843

Töötajad

800

EBITDA

44M

-148M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+18.06% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. nov 2025

Turustatistika

By TradingEconomics

Turukapital

236M

2.8B

Eelmine avamishind

9.39

Eelmine sulgemishind

5.64

Uudiste sentiment

By Acuity

100%

0%

358 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2025, 23:28 UTC

Kuumad aktsiad

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. okt 2025, 23:07 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13%

30. okt 2025, 00:00 UTC

Tulu

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. okt 2025, 23:40 UTC

Tulu

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. okt 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. okt 2025, 23:25 UTC

Tulu

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. okt 2025, 22:51 UTC

Tulu

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. okt 2025, 22:45 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. okt 2025, 22:09 UTC

Tulu

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. okt 2025, 22:08 UTC

Market Talk
Tulu

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. okt 2025, 21:58 UTC

Tulu

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. okt 2025, 21:58 UTC

Tulu

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. okt 2025, 21:57 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. okt 2025, 21:54 UTC

Tulu

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. okt 2025, 21:46 UTC

Tulu

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. okt 2025, 21:43 UTC

Tulu

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. okt 2025, 21:43 UTC

Tulu

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. okt 2025, 21:41 UTC

Tulu

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. okt 2025, 21:40 UTC

Tulu

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. okt 2025, 21:39 UTC

Tulu

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

18.06% tõus

12 kuu keskmine prognoos

Keskmine 6.93 USD  18.06%

Kõrge 8 USD

Madal 4.8 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

358 / 373 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat